Windtree Therapeutics (WINT) announced that it has engaged New Growth Advisors, NGA, a leading life sciences consulting firm chosen by companies seeking discreet, conflict-free, and knowledgeable advice on complex M&A, asset sale, research, capital markets, and licensing transactions, as its strategic advisor to lead a process in respect of Windtree’s cardiovascular portfolio, including a potential out-licensing transaction or asset sale. NGA has advised on transactions with an aggregate value approaching $400 million from 2023 through 2024.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WINT:
- Windtree Therapeutics Reports Q3 2024 Financial Results
- Windtree Therapeutics reports Q3 EPS ($4.23) vs. ($15.47) last year
- Windtree Therapeutics Appoints Jed Latkin as New CEO
- Windtree Therapeutics announces CEO Fraser to retire, Latkin to succeed
- Windtree Therapeutics Inc (WINT) Q3 Earnings Cheat Sheet